Reviewing Trinity Biotech (TRIB) and Its Peers

Trinity Biotech (NASDAQ: TRIB) is one of 24 public companies in the “Diagnostic substances” industry, but how does it compare to its competitors? We will compare Trinity Biotech to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares Trinity Biotech and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Trinity Biotech $99.14 million $2.30 million 19.54
Trinity Biotech Competitors $308.35 million $18.66 million -39.62

Trinity Biotech’s competitors have higher revenue and earnings than Trinity Biotech. Trinity Biotech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings for Trinity Biotech and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech 0 0 0 0 N/A
Trinity Biotech Competitors 101 367 567 19 2.48

As a group, “Diagnostic substances” companies have a potential upside of 15.07%. Given Trinity Biotech’s competitors higher probable upside, analysts clearly believe Trinity Biotech has less favorable growth aspects than its competitors.

Risk & Volatility

Trinity Biotech has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Trinity Biotech’s competitors have a beta of 1.44, suggesting that their average stock price is 44% more volatile than the S&P 500.

Insider and Institutional Ownership

62.1% of Trinity Biotech shares are held by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are held by institutional investors. 12.7% of Trinity Biotech shares are held by company insiders. Comparatively, 13.5% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Trinity Biotech and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trinity Biotech -40.62% 2.37% 0.99%
Trinity Biotech Competitors -884.88% -64.84% -17.51%

About Trinity Biotech

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

James River Group  Upgraded to Hold by BidaskClub
James River Group Upgraded to Hold by BidaskClub
MGM Growth Properties  Stock Rating Upgraded by Zacks Investment Research
MGM Growth Properties Stock Rating Upgraded by Zacks Investment Research
PulteGroup  Upgraded to “Buy” by B. Riley
PulteGroup Upgraded to “Buy” by B. Riley
Nexeo Solutions  Lowered to “Hold” at Zacks Investment Research
Nexeo Solutions Lowered to “Hold” at Zacks Investment Research
The Walt Disney  Upgraded to “Market Perform” by BMO Capital Markets
The Walt Disney Upgraded to “Market Perform” by BMO Capital Markets
STMicroelectronics  Posts  Earnings Results, Beats Estimates By $0.01 EPS
STMicroelectronics Posts Earnings Results, Beats Estimates By $0.01 EPS


© 2006-2018 Ticker Report. Google+.